TORONTO, Nov. 20 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL had received approval in Canada to manufacture and market Tamsulosin Hydrochloride Capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD). This product has proven to be bio- equivalent to Flomax(R) Capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH). The total market for both generic and brand Tamsulosin Hydrochloride Capsules in Canada is CAD $22 million (IMS-MAT: March 2007).
